PTO/SE/88 (07-02)

Approved for use through 7/31/2003. OMB 0851-305:

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	<u>.clid (C a Clifficon of Information Unless it disclays a valid CMS Control number.</u>				
REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14					
	in re Application of WEISS				
Aring completed form to: File Information Unit Crystal Plaza Turee, Room 1001 2021 South Clark Place Arlington, VA Telephone: (703) 308-2733	Application Number 104 Filed 7 95 108 385404 Filed 7 95 7 95 95 95 95 95				
File Information Unit I hereby request access under 37 CFR 1.14(a)(1)(iv) to the appropriation, which is identified in, or to which a benefit is claimattachment): United States Patent Application Publication No.	nlication file record of the above-identified ABANDONED med, in the following document (as shown in the				
United States Patent Number 5851832 , colu	ımn, line,or				
Related Information about Access to Pending a Direct access to pending applications is not available to the purchased from the Office of Public Records upon payment of For published applications that are still pending, a member of the file contents; the pending application as originally filed; or any document in the file of the pending application. For unpublished applications that are still pending: (1) If the benefit of the pending application is claimed under application that has: (a) issued as a U.S. patent, or (b) patent application publication, or an international patent Article 21(2), a member of the public may obtain a copy the file contents; the pending application as originally filed; or any document in the file of the pending application.	ne public but copies may be available and may be if the appropriate fee (37 CFR 1.19(b)), as follows: if the public may obtain a copy of: or 35 U.S.C. 119(e), 120, 121, or 365 in another published as a statutory invention registration, a U.S. application publication in accordance with PCT of:				

(2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in

accordance with PCT Article 21(2), a member of the public may obtain a copy of: the pending application as originally filed. FOR PTO USE ONLY Typed or printed name Approved by: Registration Number, if applicable Unit File Information Unit Telephone Number

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Sox 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA



United States Patent [19]

Weiss et al.

[11] Patent Number:

5,851,832

[45] Date of Patent:

Dec. 22, 1998

[54] IN VITRO GROWTH AND PROLIFERATION OF MULTIPOTENT NEURAL STEM CELLS AND THEIR PROGENY

[75] Inventors: Samuel Welss; Brent Reynolds, both of Alberta, Canada; Joseph P.

Hammang; E. Edward Baetge, both of

Barrington, R.I.

[73] Assignee: Neurospheres, Ltd., Canada

[21] Appl. No.: 486,648

[22] Filed: Jun. 7, 1995

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 270,412, Jul. 5, 1994, abandoned, which is a continuation of Ser. No. 726,812, Jul. 8, 1991, abandoned, and a continuation-in-part of Ser. No. 385,494, Fsb. 7-1995, abandoned, which is a continuation of Ser. No. 961,813, Oct. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 726,812, and Ser. No. 359, 945, Dec. 20, 1994, abandoned, which is a continuation of Ser. No. 221,655, Apr. 1, 1994, abandoned, which is a continuation of Ser. No. 967,622, Oct. 28, 1992, abandoned, which is a continuation-in-part of Ser. No. 726,812, Jul. 8, 1991, abandoned, and Ser. No. 376,062, Jan. 20, 1995, abandoned, which is a continuation of Ser. No. 10,829, Jan. 29, 1993, abandoned, which is a continuation-in-part of Ser. No. 726,812, and Ser. No. 311,099, Sep. 23, 1994, abandoned, which is a continuation-in-part of Ser. No. 311,099, Sep. 23, 1994, abandoned, which is a continuation-in-part of Ser. No. 338, 730, Nov. 14, 1994, abandoned, which is a continuation-in-part of Ser. No. 726,812.

[51]	Int. Cl.6	C12N 5/06; C12N 5/08;
		C12N 5/02
[52]	U.S. Cl 435/	368; 435/325; 435/366;
` '		435/383; 435/384
[58]	Field of Search	435/240.2, 325,
		366, 368, 377, 383, 384

[56] References Cited

U.S. PATENT DOCUMENTS

4.753,635	6/1988	Sagen et al 604/49
4,980,174	12/1990	Sagen et al 424/563
5,082,670	1/1992	Gage 424/520
5,175,103	12/1992	Lee et al 435/172.3
5,411,883		Boss et al 435/29
5,612,211	3/1997	Wilson et al 435/378

FOREIGN PATENT DOCUMENTS

0 233 838	8/1987	European Pat. Off
89/03872	5/1989	WIPO.
90/06757	6/1990	WIPO .
91/02003	2/1991	WIPO .
91/09936	7/1991	WIPO .
91/17242	11/1991	WIPO .
93/01275	1/1993	WIPO .
93/09802	5/1993	WIPO .
94/03199	2/1994	WIPO .

OTHER PUBLICATIONS

Almazan et al., "Epidermal Growth and Bovine Growth Hormone Stimulate Differentiation and Myelination of Brain Cell Aggregates in Culture," *Developmental Brain Research*, 21:257–264 (1985).

Anchan et al., "Trophic Factors Influence Proliferation of Germinal Neuroepithelial Cells of the Retina," J. Cell Biol., 109:58a, Abstract No. 308 (1989).

Anchan et al., "EGF and TGF- α Stimulate Retinal Neuroepithelial Cell Proliferation in Vitro," *Neuron*, 6(6):923-936 (1991).

Bayer et al., "Neuron production in the Hippocampus and olfactory bulb of the adult rat Brain: addition or replacement?", Annals NY. Acad. Sci. 457:163–172 (1985).

Björklund et al., "Neural Grafting in Animal Models of Neurodegenerative Diseases," Ann. New York Acad. Sci., 457:53-81 (1985).

Bouvier et al., "Basic Fibroblast Growth Factor (bFGF) Promotes the Survival and Proliferation of Mesencephalic Neuronal Precursors in Vitro," Society for Neuroscience Abstracts, vol. 18, Abstract No.: 403.7 (1992).

Boyles et al., "Accumulation of Apolipoproteins in the Regenerating and Remyelinating Mammalian Peripheral Nerve," J. Biol. Chem., 265(29):17805-17815 (1990).

Calof et al., "Analysis of Neurogenesis in a Mammalian Neuroepithelium: Proliferation and Differentiation of an Olfactory Neuron Precursor in Vitro," *Neuron*, 3:115–127 (1989).

Cattaneo et al., "Identifying and Manipulating neuronal stem cells," TINS, 14(8): 338-340 (1991).

Cattaneo et al., "Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor," *Nature*, 347:762–765 (1990).

Cepko "Immortalization of neural cells via retrovirus-mediated oncogene transduction," Ann. Rev. Neurosci., 12:47-65 (1989).

Deloulme et al., "Establishment of Pure Neuronal Cultures From Fetal Rat Spinal Cord and Proliferation of the Neuronal Precursor Cells in the Presence of Fibroblast Growth Factor," Journal of Neuroscience Research, 29:499–509 (1991).

Dunnett et al., "Dopamine-rich transplants in experimental Parkinsonism," TINS, 266-270 (Jul. 1983).

Emerich et al., "Behavioral Effects of Neural Transplantation," Cell Transplantation, 1:1-27 (1992).

Faaland et al., "Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity", Mol. Cell Biol. 11(5):2697-2703 (1991).

(List continued on next page.)

Primary Examiner—George C. Elliott
Assistant Examiner—Johnny F. Railey, II
Attorney, Agent, or Firm—Flehr Hohbach Test Albrition &
Herbert LLP

[57] ABSTRACT

A method for the in vitro proliferation and differentiation of neural stem cells and stem cell progeny comprising the steps of (a) isolating the cells from a mammal, (b) exposing the cells to a culture medium containing a growth factor, (c) inducing the cells to proliferate, and (d) inducing the cells to differentiate is provided.

80 Claims, 3 Drawing Sheets